As of today (2024-04-19), ALX Oncology Holdings's share price is $15.60. ALX Oncology Holdings's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $3.80. Hence, ALX Oncology Holdings's Price to Tangible Book Ratio of today is 4.11.
The historical rank and industry rank for ALX Oncology Holdings's Price-to-Tangible-Book or its related term are showing as below:
ALXO'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.75 Med: 3.16 Max: 7.99
Current: 4.11
During the past 6 years, ALX Oncology Holdings's highest Price to Tangible Book Ratio was 7.99. The lowest was 1.75. And the median was 3.16.
ALXO's Price-to-Tangible-Book is ranked worse than 66.39% of 1223
companies
in the Biotechnology industry
Industry Median: 2.7
vs ALXO: 4.11
A closely related ratio is called PB Ratio. As of today, ALX Oncology Holdings's share price is $15.60. ALX Oncology Holdings's Book Value per Sharefor the quarter that ended in Dec. 2023 was $3.80. Hence, ALX Oncology Holdings's P/B Ratio of today is 4.11.
ALX Oncology Holdings Price-to-Tangible-Book Historical Data
The historical data trend for ALX Oncology Holdings's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
ALX Oncology Holdings Annual Data
Trend
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
-
7.99
2.40
1.75
3.92
ALX Oncology Holdings Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
1.75
0.77
1.45
1.17
3.92
Competitive Comparison
For the Biotechnology subindustry, ALX Oncology Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
ALX Oncology Holdings Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of ALX Oncology Holdings's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
ALX Oncology Holdings (ALX Oncology Holdings) Business Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXO has been successfully added to your 